Summary of current recommendations for pneumococcal vaccination
| Patient population | Dosing |
|---|---|
| ≥ 65 years old | 1 dose of PPSV23 If PPSV23 was given before age 65, give another dose at least 5 years after previous dose |
| ≥ 65 years old, immunocompetent, with chronic heart disease, chronic lung disease, chronic liver disease, diabetes mellitus, alcoholism, or cigarette smoking | Shared clinical decision-making: can give PCV13 followed by PPSV23 at least 1 year later |
| 19 through 64 years old, with chronic heart (excluding hypertension), lung, or liver disease, diabetes, alcoholism, or cigarette smoking | 1 dose of PPSV23 |
| 19 through 64 years old, with cerebrospinal fluid leak or cochlear implants | 1 dose of PCV13 followed by 1 dose of PPSV23 at least 8 weeks later At age 65 or older, give another dose of PPSV23 at least 5 years after PPSV23 (only 1 dose of PPSV23 recommended for ages 65 or older) |
| 19 years or older, with congenital or acquired immunodeficiency (including B- and T-lymphocyte deficiency, complement deficiencies, phagocytic disorders, HIV infection), chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancy, iatrogenic immunosuppression (eg, drug or radiation therapy), solid organ transplant, multiple myeloma, or anatomical or functional asplenia, including sickle cell disease and other hemoglobinopathies | 1 dose of PCV13 followed by 1 dose of PPSV23 at least 8 weeks later, then another PPSV23 dose at least 5 years after previous PPSV23 At age 65 or older, give 1 dose of PPSV23 at least 5 years after most recent PPSV23 dose (only 1 dose of PPSV23 is recommended for ages 65 or older) |
PCV13 = 13-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine.
Based on information in reference 1.